SUMMARY Early embryonic patterning events are strikingly precise. The underlying molecular details are elusive and appear incompatible with stochastic gene expression observed across phyla. Using single molecule mRNA quantification in Drosophila embryos, we determine the magnitude of fluctuations in the expression of four critical patterning genes. The accumulation of mRNAs is identical across genes and fluctuates by ~8% between neighboring nuclei to generate precise protein distributions. In contrast, transcribing loci exhibit an intrinsic noise of ~45% independent of specific promoter-enhancer architecture or fluctuating inputs. The embryo recovers precise transcript distribution through straightforward spatiotemporal averaging without regulatory feedback. The common expression characteristics shared between genes suggest that the noise of fundamental physical constraints dominates the fluctuations of immediate transcriptional readout.

mRNA localization is a conserved mechanism for spatial control of protein synthesis, with key roles in generating cellular and developmental asymmetry. While different transcripts may be targeted to the same subcellular domain, the extent to which their localization is coordinated is unclear. Using quantitative single molecule imaging, we analyzed the assembly of Drosophila germ plasm mRNA granules inherited by nascent germ cells. We find that the germ cell-destined transcripts nanos, cyclin B, and polar granule component travel within the oocyte as ribonucleoprotein particles containing single mRNA molecules but co-assemble into multi-copy heterogeneous granules selectively at the posterior of the oocyte. The stoichiometry and dynamics of assembly indicate a defined stepwise sequence. Our data suggest that co-packaging of these transcripts ensures their effective segregation to germ cells. In contrast, compartmentalization of the germline determinant oskar mRNA into different granules limits its entry into germ cells. This exclusion is required for proper germline development.

Patients with classic fibrodysplasia ossificans progressiva, a disorder characterized by extensive extraskeletal endochondral bone formation, share a recurrent mutation (R206H) within the glycine/serine-rich domain of ACVR1/ALK2, a bone morphogenetic protein type I receptor. Through a series of in vitro assays using several mammalian cell lines and chick limb bud micromass cultures, we determined that mutant R206H ACVR1 activated BMP signaling in the absence of BMP ligand and mediated BMP-independent chondrogenesis that was enhanced by BMP. We further investigated the interaction of mutant R206H ACVR1 with FKBP1A, a glycine/serine domain-binding protein that prevents leaky BMP type I receptor activation in the absence of ligand. The mutant protein exhibited reduced binding to FKBP1A in COS-7 simian kidney cell line assays, suggesting that increased BMP pathway activity in COS-7 cells with R206H ACVR1 is due, at least in part, to decreased binding of this inhibitory factor. Consistent with these findings, in vivo analyses of zebrafish embryos showed BMP-independent hyperactivation of BMP signaling in response to the R206H mutant, resulting in increased embryonic ventralization. These data support the conclusion that the mutant R206H ACVR1 receptor in FOP patients is an activating mutation that induces BMP signaling in a BMP-independent and BMP-responsive manner to promote chondrogenesis, consistent with the ectopic endochondral bone formation in these patients. IntroductionFibrodysplasia ossificans progressiva (FOP; MIM 135100), a rare genetic disorder of progressive extraskeletal (heterotopic) ossification, is the most severe form of human heterotopic ossification known and results in profoundly decreased mobility of affected individuals (1). Patients with classic FOP have congenital malformation of the great toes and develop progressive heterotopic ossification within soft connective tissues in characteristic anatomic patterns (2, 3). Ectopic bone formation in FOP occurs through an endochondral pathway in which cartilage forms initially at the lesional site and is subsequently replaced by bone (4, 5). The genetic mutation in FOP is therefore a likely key regulator of cartilage and bone formation.The gene mutation for patients with the classic FOP clinical phenotype was mapped to chromosome 2q23-24, and mutations were identified in activin A receptor, type I (ACVR1; also known as ALK2), which encodes a bone morphogenetic protein (BMP) type I receptor (6). ACVR1 is expressed in several tissues, including cartilage and skeletal muscle, consistent with both the congenital skeletal malformations and the sites of postnatal endochondral het-